Evaluation of therapeutic effects of tetramethylpyrazine nitrone in Alzheimer’s disease mouse model and proteomics analysis
暂无分享,去创建一个
Q. Hou | Yuqiang Wang | Xifei Yang | Zaijun Zhang | Xinhua Zhou | Kaipeng Huang | Yingying Liu | M. Hoi
[1] M. Beal,et al. The role of mitochondrial dysfunction in Alzheimer's disease pathogenesis , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.
[2] L. Jiménez‐Díaz,et al. Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer’s disease: a systematic review , 2021, Ageing Research Reviews.
[3] Mayank Gupta,et al. Aducanumab as a Novel Treatment for Alzheimer’s Disease: A Decade of Hope, Controversies, and the Future , 2021, Cureus.
[4] M. Sabbagh,et al. The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis , 2019, Alzheimer's & Dementia.
[5] Bin Zhang,et al. Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation , 2019, bioRxiv.
[6] Yuqiang Wang,et al. Memantine Improves Cognitive Function and Alters Hippocampal and Cortical Proteome in Triple Transgenic Mouse Model of Alzheimer's Disease , 2019, Experimental neurobiology.
[7] Yuqiang Wang,et al. Hippocampal Proteomic Alteration in Triple Transgenic Mouse Model of Alzheimer's Disease and Implication of PINK 1 Regulation in Donepezil Treatment. , 2018, Journal of proteome research.
[8] T. Cassano,et al. Proteomic identification of altered protein O-GlcNAcylation in a triple transgenic mouse model of Alzheimer's disease. , 2018, Biochimica et biophysica acta. Molecular basis of disease.
[9] Irving E. Vega,et al. Ezrin Expression is Increased During Disease Progression in a Tauopathy Mouse Model and Alzheimer's Disease. , 2018, Current Alzheimer research.
[10] G. Juhász,et al. Early Presymptomatic Changes in the Proteome of Mitochondria-Associated Membrane in the APP/PS1 Mouse Model of Alzheimer’s Disease , 2018, Molecular Neurobiology.
[11] Wei Liu,et al. Neuroprotective Effect and Mechanism of Action of Tetramethylpyrazine Nitrone for Ischemic Stroke Therapy , 2018, NeuroMolecular Medicine.
[12] M. Geng,et al. Alzheimer’s disease hypothesis and related therapies , 2018, Translational Neurodegeneration.
[13] S. Campello,et al. Mitophagy in neurodegenerative diseases , 2017, Neurochemistry International.
[14] L. Lue,et al. PINK1 signalling rescues amyloid pathology and mitochondrial dysfunction in Alzheimer’s disease , 2017, Brain : a journal of neurology.
[15] Huan Chen,et al. iTRAQ-based Proteomic Analysis of APPSw,Ind Mice Provides Insights into the Early Changes in Alzheimer’s Disease , 2017, Current Alzheimer research.
[16] B. Ueberheide,et al. Proteomic differences in amyloid plaques in rapidly progressive and sporadic Alzheimer’s disease , 2017, Acta Neuropathologica.
[17] M. Z. Cader,et al. Mitophagy and Alzheimer’s Disease: Cellular and Molecular Mechanisms , 2017, Trends in Neurosciences.
[18] Z. Leonenko,et al. Recent Progress in Alzheimer's Disease Research, Part 1: Pathology. , 2017, Journal of Alzheimer's disease : JAD.
[19] Yuqiang Wang,et al. Tetramethylpyrazine nitrone, a multifunctional neuroprotective agent for ischemic stroke therapy , 2016, Scientific Reports.
[20] M. Sastre,et al. Mechanisms of Aβ Clearance and Degradation by Glial Cells , 2016, Front. Aging Neurosci..
[21] J. Hardy,et al. The amyloid hypothesis of Alzheimer's disease at 25 years , 2016, EMBO molecular medicine.
[22] Eric Karran,et al. The Cellular Phase of Alzheimer’s Disease , 2016, Cell.
[23] Azza A Ali,et al. Alzheimer's Disease: Pathophysiology, Hypotheses and Treatment Strategies , 2016 .
[24] N. Jha,et al. Impact of Insulin Degrading Enzyme and Neprilysin in Alzheimer's Disease Biology: Characterization of Putative Cognates for Therapeutic Applications. , 2015, Journal of Alzheimer's disease : JAD.
[25] Sonia Gandhi,et al. Enhancing nucleotide metabolism protects against mitochondrial dysfunction and neurodegeneration in a PINK1 model of Parkinson’s disease , 2014, Nature Cell Biology.
[26] S. Love,et al. A&bgr;-Degrading Enzymes: Potential for Treatment of Alzheimer Disease , 2011, Journal of neuropathology and experimental neurology.
[27] D. Selkoe. Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.
[28] N. Belyaev,et al. Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease. , 2008, Current Alzheimer research.
[29] J. Buxbaum,et al. Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease , 2007, Neurobiology of Aging.
[30] M. Higuchi,et al. Metabolism of amyloid-β peptide and Alzheimer's disease , 2005 .
[31] N. Nalivaeva,et al. Targeting Amyloid‐Degrading Enzymes as Therapeutic Strategies in Neurodegeneration , 2004, Annals of the New York Academy of Sciences.
[32] D. Selkoe,et al. Enhanced Proteolysis of β-Amyloid in APP Transgenic Mice Prevents Plaque Formation, Secondary Pathology, and Premature Death , 2003, Neuron.
[33] D. Butterfield,et al. Proteomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration , 2003, Journal of neurochemistry.
[34] M. Mattson,et al. Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.
[35] Mark S. Shearman,et al. Amyloid-β Hypothesis of Alzheimer’s Disease , 1998 .